AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05644236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouthwash
Description: After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hrs before the visit.
Study NCT05609721 — intervention group
Intervention type: OTHER
Intervention: no intervention, only observational study
Description: no intervention, only observational study
Study NCT05356598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Authority-delivered Health promotion video
Description: A video delivered by a US Army Lieutenant Colonel (authority figure) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
Study NCT05356598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-delivered Health Promotion Video
Description: A video delivered by a US Army ROTC cadet (peer) encouraging participants to seek help for musculoskeletal injuries experienced while in ROTC.
Study NCT05356598 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group Video
Description: Video of a US Army First Lieutenant squatting, bench pressing, and deadlifting with voiceover. No mention of musculoskeletal injuries or help-seeking behavior.
Study NCT05233683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal penile nerve block plus ring block
Description: It will be performed with the child in the supine position. Following skin preparation and palpation of the arch of the lower border of the symphysis pubis, the base of the penis will be gently pulled down, and a 25-G needle will be inserted at 10 and 2.0 O clock position to a depth of 0.25-0.5 cm (under Bucks' fascia) and 1 ml + 0.1ml X weight of the patient) of local anesthetic (0.25% bupivacaine) will be injected at each point after negative aspiration and then RB will be done in the form of a circumferential subcutaneous ring at the level of the base of the penis. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
Study NCT05233683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumcision with Plastibell
Description: Circumcision with Plastibell
Study NCT05233683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumcision with Plastibell
Description: Circumcision with Plastibell
Study NCT05233683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Dissection Method
Description: Conventional Dissection Method
Study NCT05233683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dissection Method
Description: Conventional Dissection Method
Study NCT06659536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device
Description: Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar URO device using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling.
Study NCT06377371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain Imaging with [Cu64]DOTATATE
Description: Patients will undergo a \[Cu64\]DOTATATE PET/MRI or PET/CT before undergoing radio- guided surgery. Patients will undergo another \[Cu64\]DOTATATE PET/MRI or PET/CT 6 weeks- 3 months after their surgery, and 6 months- 12 months after surgery.
Study NCT06377371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio-guided Surgery With Neoprobe Utilization
Description: After the subjects undergo the preoperative \[Cu64\]DOTATATE PET/MRI, subjects will undergo radio-guided surgery in which the surgeon will utilize a standard intraoperative gamma probe (Neoprobe Gamma Detection System ®) to assess primary/residual tumor detection.
Study NCT05033301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nurse Ned Clinic
Description: Participants enrolled in the Nurse-led Ned Clinic will receive virtual PCa survivorship follow-up care from both their specialist and an oncology nurse for one year.
Study NCT06665893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digi-physical treatment tool
Description: A support tool named Evira will be used to provide behavioral treatment. Through daily weightings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored.
Study NCT05579392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: Device: Bright Light Therapy Retimer
Study NCT05579392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Retimer Device
Description: Device: Placebo Retimer Device with no bright light therapy
Study NCT06621290 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured interviews on ED-patients experiences of frailty assessment with the CFS
Study NCT06665360 — intervention group
Intervention type: OTHER
Intervention: The high speed bur was used to mill the cancellous cortical bone of the lamina
Description: The high speed bur was used to mill the cancellous cortical bone of the lamina
Study NCT06685393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma (PRP)
Description: At the 1st visit, each quadrant is scaled and root planned using an ultrasonic scaler and manual instruments until tactile sensation detects smooth crown and root surfaces these procedures were repeated on both sides starting from 1st visit of treatment,2nd,4th, and 6th-week intervals local anesthetic was utilized in some instances where it was the necessary and subgingival application of (PRP) at test side only at baseline,3ed, 6th week.
Study NCT06685393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INJECTABLE PLATELET RICH FIBRIN(I-PRF)
Description: At the 1st visit, each quadrant is scaled and root planned using an ultrasonic scaler and manual instruments until tactile sensation detects smooth crown and root surfaces these procedures were repeated on both sides starting from 1st visit of treatment,2nd,4th, and 6th-week intervals local anesthetic was utilized in some instances where it was the necessary and subgingival application of (I-PRF) at test side only at baseline,3ed, 6th week.
Study NCT06684158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim
Description: 6 mg,HD d3,every 2weeks (Q2W)
Study NCT06684158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab：1200 mg，iv d1，every2 weeks (Q2W)
Study NCT06684158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel：50 mg/m2 iv gtt d1，every 2 weeks (Q2W)
Study NCT06684158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin ：85 mg/m2 iv gtt d1，every2 weeks (Q2W)
Study NCT06684158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-FU ：2600 mg/m2 ，intravenous infusion， 24h ，d1，every 2 weeks (Q2W)
Study NCT06684158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: LV：200 mg/m2 iv gtt d1，every 2 weeks (Q2W)
Study NCT01079559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplex™ P with Tobramycin
Description: All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
Study NCT01079559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simplex™ P
Description: All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
Study NCT05267392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion
Study NCT05267392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care RT/RCT
Description: standard of care RT/RCT
Study NCT06304350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab and platinum containing dual drugs
Description: After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab immunomaintenance therapy continued after surgery
Study NCT06524011 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone
Description: Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
Study NCT06524011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone
Description: Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
Study NCT05842902 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mPRISM
Description: PRISM is a brief, 1:1, skills-based resilience intervention delivered in-person by trained layperson coaches. PRISM's development was based on iterative research within the AYA oncology population, stress and coping theory, resilience theory, and successful cognitive-behavioral and mindfulness interventions. mPRISM is a digital version of the PRISM program with no in-person delivery. mPRISM includes coping skills modules: managing stress, goal-setting, cognitive reframing, and meaning-making.
Study NCT05842902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mPRISM
Description: PRISM is a brief, 1:1, skills-based resilience intervention delivered in-person by trained layperson coaches. PRISM's development was based on iterative research within the AYA oncology population, stress and coping theory, resilience theory, and successful cognitive-behavioral and mindfulness interventions. mPRISM is a digital version of the PRISM program with no in-person delivery. mPRISM includes coping skills modules: managing stress, goal-setting, cognitive reframing, and meaning-making.
Study NCT06682221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Whey protein supplementation.
Description: Protein supplementation will be provided through isolated whey protein, commonly known as whey protein isolate, which was generously donated by the Heroes Science Institute (HSI), as stated in the attached declaration. This whey protein isolate, with a vanilla flavor, is packaged in 25-gram sachets, each providing a total of 20 grams of protein per dose/sachet.
Study NCT06682221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation.
Description: Protein supplementation will be provided through isolated whey protein, commonly known as whey protein isolate, which was generously donated by the Heroes Science Institute (HSI), as stated in the attached declaration. This whey protein isolate, with a vanilla flavor, is packaged in 25-gram sachets, each providing a total of 20 grams of protein per dose/sachet.
Study NCT06682221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The resistance training protocol in the study included seven exercises: high pull, leg extension, leg curl, bicep curl, triceps pushdown, lateral raise, and machine bench press, taking about 60 minutes per session. The first week focused on familiarizing participants with the exercises to ensure proper execution before intensive training began. Training occurred three times a week for 12 weeks, with each exercise performed in 3 sets of 8 to 12 repetitions and rest periods of 1 to 2 minutes. The load was progressively increased by 2% to 10% weekly, based on participants\&#39; ability to complete repetitions with full range of motion. Assessments were conducted before training and 24 hours after the final session to evaluate the effects on physical and functional parameters.
Study NCT06682221 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resistance training
Description: The resistance training protocol in the study included seven exercises: high pull, leg extension, leg curl, bicep curl, triceps pushdown, lateral raise, and machine bench press, taking about 60 minutes per session. The first week focused on familiarizing participants with the exercises to ensure proper execution before intensive training began. Training occurred three times a week for 12 weeks, with each exercise performed in 3 sets of 8 to 12 repetitions and rest periods of 1 to 2 minutes. The load was progressively increased by 2% to 10% weekly, based on participants\&#39; ability to complete repetitions with full range of motion. Assessments were conducted before training and 24 hours after the final session to evaluate the effects on physical and functional parameters.
Study NCT06682221 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group Control
Description: The control group will not participate in any of the interventions proposed in the study, meaning it will not receive supplementation or undergo resistance training, serving as a reference to compare the results of the other intervention groups.
Study NCT06685731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: Laughter Yoga Intervention:~Laughter Yoga is composed of four stages: deep breathing exercises, clapping and warm-up exercises, childlike play, and laughter exercises. These stages are designed to remove barriers to laughter, enhance emotional expression through childlike play, and prepare the lungs for laughter exercises.~Before the Laughter Yoga session begins, participants will be introduced to both the practice itself and to Laughter Yoga in general. The session will then proceed according to the following structure:~Deep Breathing Exercises: Participants inhale through the nose for 4-5 seconds, hold their breath for 2-3 seconds, and exhale through the mouth, with lips pursed, for one second longer than the inhalation, while smiling or laughing. This exercise is performed for 10-15 minutes.~Clapping and Warm-Up Exercises: Participants clap with palms and fingertips touching, keeping their hands parallel. This stimulates acupressure points in the hands. To increase group energy, a
Study NCT04653402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrocelectomy surgery
Description: The standardized hydrocelectomy operation i.e. Eversion of the TVT sac
Study NCT04653402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocelectomy surgery
Description: The standardized hydrocelectomy operation i.e. Eversion of the TVT sac
Study NCT06685263 — intervention group
Intervention type: BEHAVIORAL
Intervention: Group 1
Description: The development group comprises 385 individuals. Following the data collection phase of the development group, the independent risk factors for the onset of delirium will be identified through statistical analysis. A delirium prediction model will then be constructed using the identified risk factors.
Study NCT05469282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood circulation device
Description: Blood circulation device of CGM MB-1701 (Ceragem Master V6)
Study NCT06685263 — intervention group
Intervention type: BEHAVIORAL
Intervention: Group 2
Description: The validation group comprises 385 individuals. The delirium prediction model created using the data from the development group will be validated by testing the data from the validation group. This will enable the evaluation of the model's fit and calibration in predicting delirium.
Study NCT06683456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMOTE
Description: The intervention combines psychoeducation, mindfulness skills, emotion regulation skills, and distress tolerance skills, along with self-monitoring of meals, behaviours and feelings.
Study NCT05657093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
Study NCT05657093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
Study NCT05657093 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
Study NCT05657093 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
Study NCT06684054 — intervention group
Intervention type: DRUG
Intervention: docetaxel, anthracycline, cyclophosphamide
Description: 1. Participants were required to receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy.~2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.~3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.
Study NCT06682845 — intervention group
Intervention type: OTHER
Intervention: Collection of data in patients' medical files
Description: * Demographic data~* Health data: body mass index, weight, tobacco consumption, history of hyperglycemia/ diabetes mellitus, Eastern Cooperative Oncology Group (ECOG) status, glomerular filtration rate, hemoglobin rate~* Cancer-related data: date of diagnosis, tumoral site, tumor histology type, histology grade, date of first metastases involvement, presence of visceral metastases, presence of liver metastases, presence of lymph node-only metastases~* Treatment-related data: previous line of treatment, co-treatment with anti-PD1, enfortumab vedotin (EV) treatment start date, EV treatment end date, EV posology, presence of EV reduction of dose or increased interval between perfusions, number of EV cycles~* Adverse events (AE)-related data: occurrence of cutaneous AE, grade of cutaneous AE, date of cutaneous AE, type of cutaneous AE, management of cutaneous AE, discontinuation of EV treatment, rechallenge of EV treatment~* Outcomes data: best overall response rate
Study NCT06682351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.
Study NCT06682351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1A
Description: 16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.
Study NCT06682351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MED
Description: 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.
Study NCT06303570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514 injection
Description: The total injection volume per lipoma will based on the lipoma size,as determined by ultrasound. Dosing scheme is presented as below:~Lipoma diameter of >0mm and \<10mm - total injection volume per lipoma: 1 mL ; total of 5 mg CBL-514.~Lipoma diameter of ≥10mm and ≤20mm - total injection volume per lipoma: 3 mL ; total of 15 mg CBL-514.~Lipoma diameter of >20mm and ≤30mm - total injection volume per lipoma: 6 mL ; total of 30 mg CBL-514.~Lipoma diameter of >30mm and ≤40mm - total injection volume per lipoma: 10 mL ; total of 50 mg CBL-514.~Lipoma diameter of >40mm and ≤50mm - total injection volume per lipoma: 20 mL ; total of 100 mg CBL-514.